News
Eurocine Vaccines discloses interim report for July 2022 – March 2023
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) hereby discloses the interim report for July 2022 to March 2023. Below is a summary of…
Eurocine Vaccines publicerar delårsrapport för juli 2022 – mars 2023
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” eller “Bolaget”) publicerar härmed delårsrapporten för juli 2022 till mars 2023. Nedan följer en kort sammanfattning av rapporten. Fullständig…
Eurocine Vaccines receives grant from Merck Group
Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) announces today that the Company has received a grant of SEK 300,000 from Merck Group (“Merck”).Read…